vaginalis strains. In silico analysis of G. vaginalis genomes revealed that strains 14018, 14019, 284 V, 315A, 1400E, 0288E, and 00703B, all of which possessed CRISPR/Cas, contained genes conferring resistance to bleomycin and methicillin [15]; http://​blast.​ncbi.​nlm.​nih.​gov/​Blast.​cgi. In addition, G. vaginalis strains 14018 and 14019 contained a gene coding for an aminoglycoside phosphotransferase that increased

resistance to aminoglycosides [15]. Selective pressure for virulence other than antibiotic resistance might also have an impact on the presence of CRISPR/Cas loci. In our study, however, the distribution of CRISPR/Cas systems was variable among the G. vaginalis strains with elevated Pifithrin-�� clinical trial virulence potential that were isolated from BV patients (Table 1). Thus, our results did not reveal a potential link between the presence of CRISPR loci and the known virulence features of the strains (Table 1). Overall, our data suggest that Eltanexor mw CRISPR-based typing does not provide a promising tool for epidemiological discrimination Selleck AZD7762 of G. vaginalis strains. Moreover, G. vaginalis genomic DNA has exhibited such a great variability [19–22] that the possibility of

developing a routine PCR using a set of specific primers for CRISPR loci amplification is doubtful. Table 1 G. vaginalis CRISPR spacers and known virulence features Strain Reference Clinical status Biotype Sialidase A Vaginolysin CRISPR         Coding gene Activity Coding gene Production level Number of spacers Number of unique spacers ATCC 14019 [15] BV ND + ND + ND 30 24 ATCC 14018 [15] BV 1 – - + ND 30 24 409-05 [15] Asymptomatic BV ND – - + ND 7 7 HMP9231 CP0027525.1 Not known ND + ND + ND – - 101 [14] BV ND + ND + ND – - 41V AEJE01000000.1 Healthy woman ND + ND + ND – - 315A AFDI01000000.1 Not known ND + ND + ND 11 0 5-1 [14] Healthy woman ND – - + ND 6 6 AMD [14] BV ND – - + ND 13 13 284V [22] Abnormal discharge & odor 1 + ND + ND 2 1 75712 [22] BV 1 + ND + ND 3 2 0288E [22] Abnormal discharge & odor 1 + ND + ND Masitinib (AB1010) 3 1 6420LIT [22] Healthy woman 2 – - + ND – - 6420B [22] Healthy woman 2 – - + ND – - 55152 [22]

Asymptomatic BV 3 + ND + ND – - 1400E [22] Nugent score 9 4 + ND + ND 1 1 1500E [22] Nugent score 7 5 + ND + ND 5 5 00703Bmash [22] BV 2 or 5 + ND + ND 13 11 00703C2mash [22] BV 2 or 5 + ND + ND 6 3 00703Dmash [22] BV 3 or 7 + ND + ND – - 6119V5 [22] Nugent score 5 7 + ND + ND 8 7 GV15 [18] BV 5 + S + Low – - GV17 [18] BV 5 + S + Low – - GV21 [18] BV 1 + W + Medium 11 10 GV22 [18] BV 2 + – + Low 30 13 GV23 [18] BV 1 + W + High – - GV24 [18] BV 1 + – + Low – - GV25 [18] BV 1 + W + Low 50 40 GV26 [18] BV 1 + – + Low – - GV28 [18] BV 5 + S + High 37 25 GV29 [18] BV 1 + – + Low – - GV30 [18] BV 1 + – + Low 29 27 GV31 [18] BV 1 + W + Medium – - GV32 [18] BV 1 + – + Medium – - GV33 [18] BV 5 + S + Low 18 14 GV34 [18] BV 4 + – + Low – - GV35 [18] BV 5 + S + Low – - GV36 [18] BV 2 + S + Medium – - ND – not done.